Nel ASA's Rally Defies Wall of Analyst Sell Ratings as Chairman Puts His Money Where His Mouth Is

Nel ASA shares hit a 52-week high on new electrolyzer technology, but order intake collapsed 73% and analysts rate it a sell. Insider buying contrasts with deep skepticism.

Nel ASA’s stock has staged a remarkable recovery in 2026, yet the fundamental case remains deeply divided. While shares closed Friday at EUR 0.33 — a new 52-week high and a 13.89% single-day gain — the company's order pipeline tells a far grimmer story. The disconnect between market euphoria and operational reality has rarely been this stark.

Since the start of the year, the Norwegian hydrogen pure-play has surged 71.10%, and over the past month alone it has climbed 62.38%. The rally has pushed the stock 43% above its 50-day moving average and nearly 60% above the 200-day line. That kind of stretch, combined with annualized 30-day volatility of 100%, signals a market that is pricing in hope rather than proven results.

Technology Breakthrough Underpins the Optimism

The catalyst for the latest leg higher came in early May, when Nel launched a new pressurized alkaline electrolyzer platform after eight years of development. The company claims the technology can bring the cost of a turnkey 25 MW plant to under $1,450 per kilowatt — a clear competitive advantage in an industry where cost reduction is paramount. A 70% cost cut on the stack level is targeted for the next-generation PEM prototype by 2026, with the alkaline platform already generating its first concrete order of around NOK 70 million for the second quarter.

That order, along with two PEM agreements valued at $7 million each secured in April — one from a US utility, another from a European project — provided some relief after a brutal first quarter. Revenue slipped 5% year-on-year to NOK 148 million, while headline EBITDA came in at minus NOK 100 million, an improvement of NOK 15 million from a year earlier. But the real damage was in new business: order intake collapsed 73% to just NOK 85 million, and the order backlog shrank 24% to NOK 1.113 billion.

Insider Vote of Confidence vs. Analyst Skepticism

The sharp decline in fresh orders has done little to shake the confidence of Chairman Arvid Moss. Just after the first-quarter report, he bought 100,000 shares at an average price of NOK 2.25 — a clear insider bet on the turnaround. That purchase stands in glaring contrast to the analyst community, where not a single sell-side voice recommends buying. Seven analysts rate the stock a sell, and the 12-month consensus price target of NOK 2.12 sits well below the current Oslo listing of NOK 3.22. RBC Capital Markets maintains "Neutral," Berenberg continues to recommend "Hold."

The technical picture adds to the caution. The Relative Strength Index stands at roughly 28, a level normally interpreted as oversold, though the recent rally has skewed that reading. The stock's 52-week low of EUR 0.18 in March now seems distant, but the path from here requires fundamental justification that has yet to materialize.

Cost Discipline Preserves Cash for R&D

Management is responding to the weak demand environment with aggressive cost cutting. Headcount has been reduced to around 300, a 26% decline from the peak and a 19% drop year-on-year. Personnel costs fell 21% in the first quarter versus the prior-year period. Importantly, research and development spending remains protected — a signal that Nel intends to compete on technology rather than price.

On the balance sheet, the company retains flexibility. Cash and equivalents stood at NOK 1.4 billion at quarter-end, with a further EUR 11 million in EU funding expected. That buffer allows Nel to weather the current demand trough, but the market wants proof that the new alkaline platform can convert interest into signed contracts. The PEM segment remains a drag, with revenue down 14% and EBITDA worsening by NOK 16 million, partly due to delayed or cancelled US grants.

What Comes Next: The July Test

The next major checkpoint is July 15, when Nel reports its first-half results. Investors will be looking for a steady stream of firm orders from the new druckalkalischen platform, beyond the initial NOK 70 million booking. At the Herøya facility, a EU-supported production line is slated to reach 500 MW capacity by the end of 2026. Whether that capacity gets utilized depends entirely on whether the cost story convinces skeptical buyers.

For now, the chairman has bet NOK 225,000 of his own money that the company’s technology will carry it through. The analysts, however, are betting the other way. The next few months will determine which side is right.